0001453687-24-000063.txt : 20240410 0001453687-24-000063.hdr.sgml : 20240410 20240410214019 ACCESSION NUMBER: 0001453687-24-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SPRINGER TIMOTHY A CENTRAL INDEX KEY: 0001055624 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 24836988 MAIL ADDRESS: STREET 1: 36 WOODMAN ROAD CITY: CHESTNUT HILL STATE: MA ZIP: 02467 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc. CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC DATE OF NAME CHANGE: 20090109 4 1 wk-form4_1712799609.xml FORM 4 X0508 4 2024-04-08 0 0001453687 Cartesian Therapeutics, Inc. RNAC 0001055624 SPRINGER TIMOTHY A 36 WOODMAN ROAD CHESTNUT HILL MA 02467 1 0 1 0 0 Series A Non-Voting Convertible Preferred Stock 2024-04-08 4 M 0 123925.407 D 0 D Common Stock 2024-04-08 4 M 0 4130846 A 4379899 D Series A Non-Voting Convertible Preferred Stock 2024-04-08 4 M 0 24785.081 D 0 I See Footnote Common Stock 2024-04-08 4 M 0 826169 A 1927630 I See Footnote Common Stock 3493 I By wife Stock Option (Right to Buy) 19.656 2034-01-01 Common Stock 7600 7600 D Warrant (Right to Buy) 46.50 2022-04-11 2027-04-11 Common Stock 167040 167040 I See Footnote On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock. On April 4, 2024, the issuer effected the "Reverse Stock Split". The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant. /s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer 2024-04-10